Skip to main content
WeightCited

Berberine PCOS-Related Weight Management

C エビデンス 小規模研究からのエビデンスは限られていますが、いくつかの肯定的なシグナルがあります。

Systematic reviews suggest berberine may be comparable to metformin for insulin resistance in PCOS. Small RCTs show improvements in BMI, testosterone, and metabolic markers. Berberine is commonly combined with inositol in clinical protocols.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'weightcited.com'; const params = 'ingredient\u003Dberberine\u0026condition\u003Dpcos\u002Dweight'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

結論

Systematic reviews suggest berberine may be comparable to metformin for insulin resistance in PCOS. Small RCTs show improvements in BMI, testosterone, and metabolic markers. Berberine is commonly combined with inositol in clinical protocols.

Key Study Findings

Review
The role of traditional Chinese medicine in modulating gut microbiota to alleviating insulin resistance in …
Dose: None vs: None Outcome: PCOS insulin resistance via gut microbiota 効果: None None

対象集団: Women with PCOS and insulin resistance

Review
Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome.
Dose: None vs: None Outcome: gut microbiota composition 効果: None None

対象集団: None

Key Statistics

6

研究数

400

参加者数

Positive

C

グレード

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:
500 mg 2-3x/day with meals
starting:
500 mg/day and titrate
metabolicsupport:
1,000-1,500 mg/day

上限量: 1,500 mg/day; GI side effects limit intake; potential drug interactions

研究で検討された用量

用量 期間 効果 N
None -- Positive --
None -- Mixed --

推奨摂取タイミング: With meals (reduces GI discomfort and synchronizes with postprandial glucose metabolism)

Safety & Side Effects

報告されている副作用

  • Diarrhea
  • Constipation
  • Flatulence
  • Abdominal pain
  • Potential hypoglycemia (when combined with diabetes medications)

既知の相互作用

  • Diabetes medications (may potentiate — hypoglycemia risk)
  • CYP3A4 substrates (berberine is a CYP3A4 inhibitor)
  • CYP2D6 substrates
  • Cyclosporine
  • Metformin (additive effects)

耐容上限摂取量: 1,500 mg/day; GI side effects limit intake; potential drug interactions

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Berberine help with PCOS-Related Weight Management?
Based on 6 studies with 400 participants, there is limited but promising evidence that Berberine may support PCOS-Related Weight Management management. Our evidence grade is C (Some Evidence).
How much Berberine should I take for PCOS-Related Weight Management?
Studies have used various dosages. A commonly studied range is 500 mg 2-3x/day with meals. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Berberine?
Reported side effects may include Diarrhea, Constipation, Flatulence, Abdominal pain. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Berberine and PCOS-Related Weight Management?
We rate the evidence as Grade C (Some Evidence). This rating is based on 6 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.

に関する他の成分: PCOS-Related Weight Management

Berberine 他の症状・状態について

References

  1. [1] Lin Yin et al.. Front Nutr. 2025. The role of traditional Chinese medicine in modulating gut microbiota to alleviating insulin resistance in polycystic ovary syndrome. doi:10.3389/fnut.2025.1700612 PubMed
  2. [2] Ting-Wei Zhu et al.. Clin Exp Pharmacol Physiol. 2023. Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome. doi:10.1111/1440-1681.13814 PubMed

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。